Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288–300. https://doi.org/10.1001/jama.2018.19323

Article  CAS  PubMed  Google Scholar 

Cataldo A, Piovan C, Plantamura I, D’Ippolito E, Camelliti S, Casalini P, Giussani M, Deas O, Cairo S, Judde JG, Tagliabue E, Iorio MV (2018) MiR-205 as a predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget 9:27920–27928. https://doi.org/10.18632/oncotarget.24723

Article  PubMed  PubMed Central  Google Scholar 

Rimawi M, De Angelis C, Contreras A, Pareja F, Geyer F, Burke K, Herrera S, Wang T, Mayer I, Forero A, Nanda R, Goetz M, Chang J, Krop I, Wolff A, Pavlick A, Fuqua S, Gutierrez C, Hilsenbeck S, Li M, Weigelt B, Reis-Filho J, Kent Osborne C, Schiff R (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731–740. https://doi.org/10.1007/s10549-017-4533-9

Article  CAS  PubMed  Google Scholar 

Choi J, Jeon C, Kim Y, Jung S (2020) Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer. Medicine 99:e23053. https://doi.org/10.1097/md.0000000000023053

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y (2010) Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J Surg Oncol 101:222–227. https://doi.org/10.1002/jso.21486

Article  CAS  PubMed  Google Scholar 

Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase J, Solbach C, Mehta K, Fasching P, Sinn B, Engels K, Reinisch M, Hansmann M, Tesch H, von Minckwitz G, Untch M (2013) HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 15:R11. https://doi.org/10.1186/bcr3384

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor-infiltrating lymphocytes are prognostic in triple-negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550. https://doi.org/10.1093/annonc/mdu112

Article  CAS  PubMed  Google Scholar 

Perez E, Thompson E, Ballman K, Anderson S, Asmann Y, Kalari K, Eckel-Passow J, Dueck A, Tenner K, Jen J, Fan J, Geiger X, McCullough A, Chen B, Jenkins R, Sledge G, Winer E, Gralow J, Reinholz M (2015) Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group n9831 adjuvant trastuzumab trial. J Clin Oncol 33:701–708. https://doi.org/10.1200/jco.2014.57.6298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varadan V, Gilmore H, Miskimen K, Tuck D, Parsai S, Awadallah A, Krop I, Winer E, Bossuyt V, Somlo G, Abu-Khalaf M, Fenton M, Sikov W, Harris L (2016) Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer. Clin Cancer Res 22:3249–3259. https://doi.org/10.1158/1078-0432.ccr-15-2021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou Y, Nitta H, Wei L, Banks P, Parwani A, Li Z (2018) Evaluation of immune reaction and PD-L1 expression using multiplex immunohistochemistry in HER2-positive breast cancer: the association with response to anti-HER2 neoadjuvant therapy. Clin Breast Cancer 18:e237–e244. https://doi.org/10.1016/j.clbc.2017.11.001

Article  CAS  PubMed  Google Scholar 

Li H (2013) Aligning sequence reads, clone sequences, and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997. https://doi.org/10.48550/arXiv.1303.3997

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352

Article  CAS  PubMed  PubMed Central  Google Scholar 

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491–498. https://doi.org/10.1038/ng.806

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC, Dry JR (2016) VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 44:e108. https://doi.org/10.1093/nar/gkw227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garrison E, Marth G (2012) Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907. https://doi.org/10.48550/arXiv.1207.3907

Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164. https://doi.org/10.1093/nar/gkq603

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, Hamamsy T, Lek M, Samocha KE, Cummings BB, Birnbaum D, The Exome Aggregation C, Daly MJ, MacArthur DG (2017) The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res 45:D840–D845. https://doi.org/10.1093/nar/gkw971

Article  CAS  PubMed  Google Scholar 

Talevich E, Shain AH, Botton T, Bastian BC (2016) CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol 12:e1004873

Article  PubMed  PubMed Central  Google Scholar 

Kawaguchi S, Higasa K, Shimizu M, Yamada R, Matsuda F (2017) HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data. Hum Mutat 38:788–797. https://doi.org/10.1002/humu.23230

Article  CAS  PubMed  Google Scholar 

Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12:357–360. https://doi.org/10.1038/nmeth.3317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923–930. https://doi.org/10.1093/bioinformatics/btt656

Article  CAS  PubMed  Google Scholar 

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287. https://doi.org/10.1089/omi.2011.0118

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550. https://doi.org/10.1073/pnas.0506580102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7. https://doi.org/10.1186/1471-2105-14-7

Article  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18:248–262. https://doi.org/10.1016/j.celrep.2016.12.019

Article  CAS  PubMed  Google Scholar 

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44. https://doi.org/10.1016/j.cell.2016.02.065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G (2005) Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304:604–619. https://doi.org/10.1016/j.yexcr.2004.12.008

Article  CAS  PubMed  Google Scholar 

Maadi H, Nami B, Tong J, Li G, Wang Z (2018) The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer 18:238. https://doi.org/10.1186/s12885-018-4143-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo P, Pu T, Chen S, Qiu Y, Zhong X, Zheng H, Chen L, Bu H, Ye F (2017) Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome. Oncol Lett 14:6562–6570. https://doi.org/10.3892/ol.2017.7051

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA (2014) EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer 111:1065–1071. https://doi.org/10.1038/bjc.2014.442

Article  CAS

留言 (0)

沒有登入
gif